Moleculin Biotech Inc MBRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Moleculin Secures Australian Patent for Annamycin Formulation Technology
Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
Moleculin Announces Reverse Stock Split
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
Trading Information
- Previous Close Price
- $8.06
- Day Range
- $7.71–8.10
- 52-Week Range
- $3.23–229.40
- Bid/Ask
- $6.35 / $10.00
- Shares Outstanding
- 1.02M
- Market Cap
- $8.02M
- Volume/Avg
- 9,901 / 44,683
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.moleculin.com
Valuation
Metric | MBRX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.24 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | MBRX |
|---|---|
Quick Ratio | 0.78 |
Current Ratio | 0.94 |
Interest Coverage | — |
Quick Ratio
MBRX
Profitability
Metric | MBRX |
|---|---|
Return on Assets (Normalized) | −294.41% |
Return on Equity (Normalized) | −4,154.14% |
Return on Invested Capital (Normalized) | −3,371.18% |
Return on Assets
MBRX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|m@#wyG | LOCK|>X%! | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|wS&&Gv | LOCK|$DW% | $99B | |||
| Moderna Inc MRNA | LOCK|S$nvNk< | LOCK|D> | $90B | |||
| argenx SE ADR ARGX | LOCK|Q<^SctJ | LOCK|ZK% | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|l#<%@<G | LOCK|<cJ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Z!g#%gP | LOCK|Vv>y | $31B | |||
| Incyte Corp INCY | LOCK|PKKmTw | LOCK|YX$ | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|#&VNRB? | LOCK|D#kt | $22B | |||
| BioNTech SE ADR BNTX | LOCK|wyq%@F! | LOCK|d# | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|t@B>vld | LOCK|nCR | $16B |